Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study assessing Allogeneic G-NK cell therapy for cancer

Trial Profile

A phase I/II study assessing Allogeneic G-NK cell therapy for cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 03 Feb 2021 According to an Indapta Therapeutics media release, this trial is expected to begin in 2H 2021.
  • 28 Oct 2020 According to a Multiple Myeloma Research Foundation media release, The Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics announced a partnership to support this trial and this collaboration is supported with an investment in Indapta by the MMRF's venture philanthropy arm, the Myeloma Investment Fund (MIF).
  • 09 Jul 2020 According to an Indapta Therapeutics media release, the company plans to initiate this study in summer 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top